FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157882311> ?p ?o ?g. }

• W2157882311 endingPage "838" @default.
• W2157882311 startingPage "833" @default.
• W2157882311 abstract "Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%–75% have clinical stage I (CSI) disease. Both surveillance and adjuvant chemotherapy may be applied with indistinguishable long-term survival rates. Therefore, the patient should decide based on risk factors and potential benefits and harms rather than adopting a uniform recommendation for all.Testicular cancer (TC) is the most common neoplasm in males aged 15–40 years. The majority of patients have no evidence of metastases at diagnosis and thus have clinical stage I (CSI) disease [Oldenburg J, Fossa SD, Nuver J et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi125–vi132; de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006; 24: 5482–5492.]. Management of CSI TC is controversial and options include surveillance and active treatment. Different forms of adjuvant therapy exist, including either one or two cycles of carboplatin chemotherapy or radiotherapy for seminoma and either one or two cycles of cisplatin-based chemotherapy or retroperitoneal lymph node dissection for non-seminoma. Long-term disease-specific survival is ∼99% with any of these approaches, including surveillance. While surveillance allows most patients to avoid additional treatment, adjuvant therapy markedly lowers the relapse rate. Weighing the net benefits of surveillance against those of adjuvant treatment depends on prioritizing competing aims such as avoiding unnecessary treatment, avoiding more burdensome treatment with salvage chemotherapy and minimizing the anxiety, stress and life disruption associated with relapse. Unbiased information about the advantages and disadvantages of surveillance and adjuvant treatment is a prerequisite for informed consent by the patient. In a clinical scenario like CSI TC, where different disease-management options produce indistinguishable long-term survival rates, patient values, priorities and preferences should be taken into account. In this review, we provide an overview about risk factors for relapse, potential benefits and harms of adjuvant chemotherapy and active surveillance and a rationale for involving patients in individualized decision making about their treatment rather than adopting a uniform recommendation for all." @default.
• W2157882311 created "2016-06-24" @default.
• W2157882311 creator A5003563674 @default.
• W2157882311 creator A5006961790 @default.
• W2157882311 creator A5009101766 @default.
• W2157882311 creator A5013261865 @default.
• W2157882311 creator A5016594552 @default.
• W2157882311 creator A5023199265 @default.
• W2157882311 creator A5024482335 @default.
• W2157882311 creator A5041610986 @default.
• W2157882311 creator A5042221345 @default.
• W2157882311 creator A5060170484 @default.
• W2157882311 creator A5062805582 @default.
• W2157882311 creator A5067619404 @default.
• W2157882311 creator A5068081109 @default.
• W2157882311 creator A5071060598 @default.
• W2157882311 creator A5075273410 @default.
• W2157882311 creator A5075511405 @default.
• W2157882311 creator A5077333954 @default.
• W2157882311 creator A5078783492 @default.
• W2157882311 creator A5082102746 @default.
• W2157882311 creator A5082776045 @default.
• W2157882311 date "2015-05-01" @default.
• W2157882311 modified "2023-10-13" @default.
• W2157882311 title "Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer" @default.
• W2157882311 cites W1995567287 @default.
• W2157882311 cites W1997773801 @default.
• W2157882311 cites W2028233263 @default.
• W2157882311 cites W2029967023 @default.
• W2157882311 cites W2038572960 @default.
• W2157882311 cites W2040995801 @default.
• W2157882311 cites W2046903761 @default.
• W2157882311 cites W2048392832 @default.
• W2157882311 cites W2065241538 @default.
• W2157882311 cites W2096730530 @default.
• W2157882311 cites W2098064059 @default.
• W2157882311 cites W2103429415 @default.
• W2157882311 cites W2105359710 @default.
• W2157882311 cites W2108328835 @default.
• W2157882311 cites W2118733633 @default.
• W2157882311 cites W2119026490 @default.
• W2157882311 cites W2120873957 @default.
• W2157882311 cites W2121671594 @default.
• W2157882311 cites W2122178864 @default.
• W2157882311 cites W2123420087 @default.
• W2157882311 cites W2131899080 @default.
• W2157882311 cites W2133441044 @default.
• W2157882311 cites W2135250589 @default.
• W2157882311 cites W2136033403 @default.
• W2157882311 cites W2140462124 @default.
• W2157882311 cites W2140944538 @default.
• W2157882311 cites W2141277278 @default.
• W2157882311 cites W2141964341 @default.
• W2157882311 cites W2143408841 @default.
• W2157882311 cites W2146458161 @default.
• W2157882311 cites W2146770164 @default.
• W2157882311 cites W2156845043 @default.
• W2157882311 cites W2158358700 @default.
• W2157882311 cites W2158551593 @default.
• W2157882311 cites W2160890421 @default.
• W2157882311 cites W2161383730 @default.
• W2157882311 cites W2163911083 @default.
• W2157882311 cites W2165106918 @default.
• W2157882311 cites W2166066062 @default.
• W2157882311 cites W2166803757 @default.
• W2157882311 cites W2167309306 @default.
• W2157882311 cites W2171697262 @default.
• W2157882311 cites W2172027353 @default.
• W2157882311 cites W2272768916 @default.
• W2157882311 cites W2597314348 @default.
• W2157882311 doi "https://doi.org/10.1093/annonc/mdu514" @default.
• W2157882311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25378299" @default.
• W2157882311 hasPublicationYear "2015" @default.
• W2157882311 type Work @default.
• W2157882311 sameAs 2157882311 @default.
• W2157882311 citedByCount "50" @default.
• W2157882311 countsByYear W21578823112015 @default.
• W2157882311 countsByYear W21578823112016 @default.
• W2157882311 countsByYear W21578823112017 @default.
• W2157882311 countsByYear W21578823112018 @default.
• W2157882311 countsByYear W21578823112019 @default.
• W2157882311 countsByYear W21578823112020 @default.
• W2157882311 countsByYear W21578823112021 @default.
• W2157882311 countsByYear W21578823112022 @default.
• W2157882311 countsByYear W21578823112023 @default.
• W2157882311 crossrefType "journal-article" @default.
• W2157882311 hasAuthorship W2157882311A5003563674 @default.
• W2157882311 hasAuthorship W2157882311A5006961790 @default.
• W2157882311 hasAuthorship W2157882311A5009101766 @default.
• W2157882311 hasAuthorship W2157882311A5013261865 @default.
• W2157882311 hasAuthorship W2157882311A5016594552 @default.
• W2157882311 hasAuthorship W2157882311A5023199265 @default.
• W2157882311 hasAuthorship W2157882311A5024482335 @default.
• W2157882311 hasAuthorship W2157882311A5041610986 @default.
• W2157882311 hasAuthorship W2157882311A5042221345 @default.
• W2157882311 hasAuthorship W2157882311A5060170484 @default.
• W2157882311 hasAuthorship W2157882311A5062805582 @default.
• W2157882311 hasAuthorship W2157882311A5067619404 @default.

• next